-
1 Comment
NetScientific plc is currently in a long term uptrend where the price is trading 84.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.4.
Finally, its free cash flow fell by 0.0% to $-507K since the same quarter in the previous year.
Based on the above factors, NetScientific plc gets an overall score of 2/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | F |
CurrencyCode | EUR |
ISIN | None |
Beta | 2.04 |
---|---|
Dividend Yield | 0.0% |
Market Cap | 1M |
PE Ratio | None |
Target Price | None |
NetScientific plc is a venture capital firm specializing in seed, early and mid stage investments. The firm focuses to invest in transformative biomedical and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases. Within digital health it focuses on data analytics, wearable technologies, and devices. The firm seeks to invest in companies based in European developed markets and in the United States. It typically invests up to $15 million, but may consider larger amounts. It prefers to hold a controlling interest in all principal subsidiaries. The firm prefers to invest through its balance sheet investments. NetScientific plc was founded in 2008 and is based in Ashford, United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NTK.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025